The Alphabet, Astellas, Novartis and WuXi AppTec-backed cancer therapy developer priced its shares at the foot of their range in an upsized offering.

TScan Therapeutics, the US-based cancer immunotherapy developer which counts internet and technology group Alphabet and pharmaceutical firms Astellas, Novartis and WuXi AppTec as investors, secured $100m in its initial public offering on Friday. The company issued almost 6.7 million shares on the Nasdaq Global Market priced at $15 each having set a range of $15…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.